tiprankstipranks
MEMSCAP SA (FR:MEMS)
:MEMS
Want to see FR:MEMS full AI Analyst Report?

MEMSCAP SA (MEMS) AI Stock Analysis

4 Followers

Top Page

FR:MEMS

MEMSCAP SA

(MEMS)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
€5.00
Action:Reiterated
Date:08/06/26
The score is primarily supported by a solid balance sheet and sustained profitability versus earlier loss years, but is held back by weakening revenue and margin trends and uneven cash-flow consistency. Technical indicators are neutral-to-mixed rather than clearly bullish, and valuation is the biggest headwind due to a high P/E versus cooling fundamentals.
Positive Factors
Balance-sheet strength
Rising equity and declining debt indicate improving capitalization and financial flexibility. A stronger balance sheet supports multi-year R&D and capital cycles in MEMS manufacturing, reduces refinancing risk, and provides capacity to pursue strategic contracts or smooth cyclical demand shocks.
Negative Factors
Top-line weakness
Sustained revenue decline since the 2023 peak erodes operating leverage and makes it harder to absorb fixed costs in a capital-intensive MEMS business. Prolonged top-line weakness risks shrinking scale advantage and pressures long-term investment in capacity and R&D.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Rising equity and declining debt indicate improving capitalization and financial flexibility. A stronger balance sheet supports multi-year R&D and capital cycles in MEMS manufacturing, reduces refinancing risk, and provides capacity to pursue strategic contracts or smooth cyclical demand shocks.
Read all positive factors

MEMSCAP SA (MEMS) vs. iShares MSCI France ETF (EWQ)

MEMSCAP SA Business Overview & Revenue Model

Company Description
Memscap, S.A. is a Crolles, France-based company, founded in 1997, that develops and delivers advanced micro-electro-mechanical systems (MEMS) solutions. Catering to a global clientele, the company serves diverse sectors including aerospace and de...
How the Company Makes Money
MEMSCAP makes money primarily by selling MEMS-based products and by providing microfabrication/manufacturing services to third parties. Key revenue streams: 1) Product sales (MEMS components/modules): The company generates revenue from supplying ...

MEMSCAP SA Financial Statement Overview

Summary
Financials are stable but not accelerating. Profitability improved versus 2020–2021 with positive net income in 2022–2025, yet revenue has declined since a 2023 peak and net margins have compressed (about ~15% in 2023 to ~7% in 2025). The balance sheet is solid with rising equity and declining debt, while cash flow is generally positive but volatile (FCF negative in 2022, weak in 2024, rebound in 2025).
Income Statement
63
Positive
Balance Sheet
72
Positive
Cash Flow
66
Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue11.99M12.66M14.07M9.34M8.54M
Gross Profit4.96M5.02M6.04M3.68M3.63M
EBITDA1.43M2.36M3.04M1.45M1.87M
Net Income894.00K1.37M2.14M1.05M-328.00K
Balance Sheet
Total Assets25.37M25.83M26.28M23.45M25.43M
Cash, Cash Equivalents and Short-Term Investments4.46M3.96M4.80M4.18M3.92M
Total Debt4.48M5.04M5.71M5.28M6.18M
Total Liabilities6.33M7.56M8.61M7.86M9.65M
Stockholders Equity19.04M18.27M17.68M15.59M15.79M
Cash Flow
Free Cash Flow1.26M342.00K1.41M-161.00K1.57M
Operating Cash Flow1.36M548.00K1.75M100.00K1.59M
Investing Cash Flow-196.00K-192.00K-491.00K1.35M-192.00K
Financing Cash Flow-665.00K-1.19M-593.00K-706.00K-738.00K

MEMSCAP SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison

MEMSCAP SA Corporate Events

MEMSCAP lifts revenue and margins on aerospace and medical demand
Jul 28, 2026
MEMSCAP reported second-quarter 2026 revenue of €3.64 million, up 19.9% year on year, with aerospace remaining the main growth engine at 71% of sales and medical revenue surging 78.8% on strong demand for invasive blood pressure monitoring. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2026